Literature DB >> 6788292

Fatal bone-marrow suppression associated with captopril.

A el-Makri, M S Larabi, C Kechrid, C Belkahia, H Ben Ayed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6788292      PMCID： PMC1506343          DOI： 10.1136/bmj.283.6286.277-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  5 in total

1.  Captopril-associated agranulocytosis.

Authors:  P van Brummelen; R Willemze; W D Tan; J Thompson
Journal:  Lancet       Date:  1980-01-19       Impact factor: 79.321

2.  Captopril associated granulocytopenia in hypertension after renal transplantation.

Authors:  F Elijovisch; L R Krakoff
Journal:  Lancet       Date:  1980-04-26       Impact factor: 79.321

3.  Captoril-associated agranulocytosis.

Authors:  F W Amann; F R Bühler; D Conen; F Brunner; R Ritz; B Speck
Journal:  Lancet       Date:  1980-01-19       Impact factor: 79.321

4.  Captopril and agranulocytosis.

Authors:  J Staessen; R Fagard; P Lijnen; A Amery
Journal:  Lancet       Date:  1980-04-26       Impact factor: 79.321

5.  Fatal pancytopenia associated with the use of captopril.

Authors:  I Gavras; L G Graff; B D Rose; J M McKenna; H R Brunner; H Gavras
Journal:  Ann Intern Med       Date:  1981-01       Impact factor: 25.391
  5 in total
  5 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

2.  Reversible captopril-associated bone marrow aplasia.

Authors:  R K Strair; W E Mitch; D V Faller; K L Skorecki
Journal:  Can Med Assoc J       Date:  1985-02-15       Impact factor: 8.262

3.  Low dose captopril in the treatment of severe refractory hypertension associated with renal failure.

Authors:  G M Bell; M L Watson; A Doig; A L Muir; R J Winney
Journal:  Postgrad Med J       Date:  1982-07       Impact factor: 2.401

Review 4.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

5.  HLA-DR2 Frequency Increase in Severe Aplastic Anemia Patients is Mainly Attributed to the Prevalence of DR15 Subtype.

Authors:  Sergey I Kapustin; Tamara I Popova; Anton A Lyschov; Alexander V Togo; Kudrat M Abdulkadyrov; Michail N Blinov
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.